Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023

Allergan Aesthetics

News provided by

AbbVie

Mar 29, 2023, 09:00 ET

Share this article

Share toX

Share this article

Share toX

-- 'Discover Your 360°' immersive experience to feature across Allergan Aesthetics events, supporting customers with all aspects of their Practice, Product and Patient needs --

-- Two expert-led Allergan Medical Institute (AMI) symposia to discuss a 360° approach to consultation and treatment, featuring live injection sessions with Dr.Mauricio de Maio and Dr. Sylwia Lipko-Godlewska –

IRVINE, Calif., March 29, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from 30 March - 1 April 2023, supporting practitioners to help patients 'unlock their individuality' in an evolving world. Events include two Allergan Medical Institute (AMI) symposia, Meet the Expert sessions and an interactive exhibition booth that practitioners can explore. Through its 360° offering, Allergan Aesthetics aims to support customers from all angles of their professional journey – Practice, Products, Patients.

Allergan Aesthetics recently launched the Future of Aesthetics Global Trends Report, commissioned to identify and understand the underlying social and cultural drivers and trends that are set to shape the industry. This year's AMI hosted symposia will explore some of the key themes identified through presentations and panel discussions with industry-leading experts. Topics covered include aesthetic individuality, treating changing patient demographics, ethics in Aesthetics, and the patient consultation -with the goal of helping customers to better prepare for the future.

Topics Covered

An in-depth look into embracing individuality is the focus of the first symposium, 'Discover Your 360° with Allergan Aesthetics: Practice, Products, Purpose'. The symposium will be co-chaired by dermatologist Dr. Shannon Humphrey (Canada) and aesthetic medical practitioner Dr. Tapan Patel (UK), with expert panel discussions and a live injection session from Dr. Sylwia Lipko-Godlewska (Poland).

The second day opens with a look to the future of aesthetics in a changing world from Carrie Strom, President, Global Allergan Aesthetics, and the symposium 'Unlocking your patient's individuality with Allergan Aesthetics 360°'. During the session, we will discuss treating patients through the ages, how to achieve age-inclusive beauty in practice, and the important role of ethics in the field of aesthetics. To end the day, plastic surgeon Dr. Mauricio de Maio (Brazil) will perform a live injection on stage.

The following symposia will take place:

  • 'Discover Your 360° with Allergan Aesthetics: Practice, Products, Purpose'. 10:45 – 12:45 on Thursday 30 March in the Salles de Princes, Grimaldi Forum.
  • 'Unlocking your patient's individuality with Allergan Aesthetics 360°'. 09:45 – 12:45 on Friday 31 March in the Salles de Princes, Grimaldi Forum.

Carrie Strom, President, Global Allergan Aesthetics comments, "AMWC is the preeminent conference for the aesthetics industry, and we look forward to connecting with experts from around the world. With top industry professionals, our AMI symposia will showcase our 360° approach to patient consultation and treatment to support customers to deliver individualised results."

Outside of the symposia, Allergan Aesthetics will showcase a series of Meet the Expert Sessions with practitioners from all over the world who will share valuable clinical insights and treatment results through a series of case study presentations, taking place on the Allergan Aesthetics exhibition booth (K2) throughout the congress. Attendees will also be able to explore the interactive areas to learn all about Allergan Aesthetics' 360° offering and its diverse portfolio of aesthetics products. 

Global Aesthetics Medical Affairs Symposium, 'Socially transformative aesthetic medicine: The intersection of social psychology, technology, and medical aesthetics', will take place on 1 April 2023 (11:00–13:00). The meeting will be fronted by a host of aesthetic experts through presentations and panel discussions exploring the science and technology behind social perception and how these can be used to deliver an individualised consultation and treatment plan.

Poster presentations include:

Efficacy of 2 doses of onabotulinumtoxina versus placebo for the treatment of masseter muscle prominence: results from a randomized, controlled, phase 2b trial with 6-month follow-up"

  • Authors: Steven Dayan, MD; Sabrina Fabi, MD; Brian Biesman, MD; Alexander Rivkin, MD; Edward Lain, MD; Julie Garcia, PhD; Tanya Brandstetter, PhD; Grace Pan, M; Beta Bowen, MS; Elisabeth Lee, MBA, MPH; Mitchell F. Brin, MD

Sustained improvements in lower facial volume, width, and angle after a single treatment with onabotulinumtoxina for masseter muscle prominence  

  • Authors: Steven Dayan MD; Steven Liew, MD; Brian Biesman, MD; Alexander Rivkin, MD; Todd Schlesinger MD; Tanya Brandstetter, PhD; Grace Pan, MS; Beta Bowen, MS; Elisabeth Lee, MBA, MPH; Mitchell F. Brin, MD

Visit our two symposia and exhibition booth K2 in the Grimaldi Forum to Discover Your 360° with Allergan Aesthetics.

Notes to Editors

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.com

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn

Footnotes:

  *  An AbbVie company  

SOURCE AbbVie

21%

more press release views with 
Request a Demo

Modal title

Also from this source

À l'occasion du 19e Congrès européen sur les céphalées, AbbVie va présenter les données de la phase 3 d'ECLIPSE démontrant la supériorité de l'atogépant (AQUIPTA®) par rapport au placebo dans le soulagement complet de la douleur pour le traitement aigu de la migraine

À l'occasion du 19e Congrès européen sur les céphalées, AbbVie va présenter les données de la phase 3 d'ECLIPSE démontrant la supériorité de l'atogépant (AQUIPTA®) par rapport au placebo dans le soulagement complet de la douleur pour le traitement aigu de la migraine

AbbVie (NYSE : ABBV) a annoncé aujourd'hui les premiers résultats de l'étude pivot de phase 3 ECLIPSE, qui évalue l'innocuité, l'efficacité et la...

AbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Akutbehandlung von Migräne belegen

AbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Akutbehandlung von Migräne belegen

AbbVie (NYSE: ABBV) hat heute die vorläufigen Ergebnisse der zulassungsrelevanten Phase-3-Studie ECLIPSE bekannt gegeben, in der die Sicherheit,...

More Releases From This Source

Explore

Cosmetics and Personal Care

Cosmetics and Personal Care

Household, Consumer & Cosmetics

Household, Consumer & Cosmetics

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.